ANTIVIRAL AGENTS AND USE THEREOF Russian patent published in 2020 - IPC C07D405/04 A61K31/4035 A61K31/41 A61K31/4192 A61P31/12 A61P31/16 

FIELD: medicine; pharmaceuticals.

SUBSTANCE: invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, where R₁ is selected from a group consisting of COOH or a salt thereof and C(O)OR₁₁, where R₁₁ is independently selected from a group, consisting of hydrogen and C₁-C₆ alkyl; R₃ is selected from a group consisting of N-bonded tetrazole, optionally substituted with optionally substituted NH₂, optionally substituted N-linked isoindole, optionally substituted N-bonded benzotriazole and N-linked triazole, substituted on one or both carbon atoms of the ring, having the following structure:

,

where R₂₀ and R₂₁ are selected from a group consisting of hydrogen, C₁-C₆ alkyl, -CH₂OCH₃, pyridyl and optionally substituted phenyl and where optionally substituted means optionally substituted with one or more groups selected from C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, NH₂, Cl, F, Br and I, provided that when R₂₀ is hydrogen and R₄ is AcHN, then R₂₁ is selected from a group consisting of hydrogen, C₁-C₆ alkyl and substituted phenyl, where substitution of phenyl is independently selected from a group, consisting of methyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, 2-methylbutyl, 3-methylbutyl, hexyl, C₁-C₆ haloalkyl, C₁-C₆ alkylhydroxy, COOH, O, Br and I, and where at least one of R₂₀ and R₂₁ is not hydrogen; R₄ denotes NHC(O)R₁₇, where R₁₇ is selected from a group consisting of C₁-C₆ alkyl and C₁-C₆ halogenoalkyl; R₆, R₇ and R₈ are independently selected from a group consisting of OH and -OC(O)R₁₈, and R₁₈ is C₁-C₆ alkyl, and provided that when R₄ is NHAc and R₃ is a triazole substituted only in position R₂₁, then triazole is not substituted with propyl substituted with propyl substituted with tert-butyl or diethoxyalkyl. Invention also relates to a pharmaceutical composition based on said compounds of formula (I).

EFFECT: technical result is obtaining a novel compound and a based pharmaceutical composition, which can be used in medicine as modulators of activity of haemagglutinin virus enzymes and/or neuraminidase for treating diseases, disorders or conditions caused by parainfluenza virus.

15 cl, 5 tbl, 26 dwg